TICKERNERD
Menu
MAZEMAZEHealthcare · Biotechnology

MAZE Stock Forecast: Maze Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$23
−3.92% on the day

The 12 Wall Street analysts covering Maze Therapeutics, Inc. hold a median 12-month price target of $55 — +144.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.3B
Ticker Nerd rank
26 / 100
Median analyst target
$55
Analysts covering
12
Revenue$0.0
Operating income−$48.0M
Net income−$44.7M
Free cash flow−$15.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.5%
1M
−22.7%
YTD
−45.6%
1Y
−4.1%
From 52W high
−56.6%
From 52W low
0.0%
$23
$52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MAZE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Maze Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
81
Value
49
Revisions
45
Size
42
Volatility
41
Quality
40
Accruals
37
Growth
28
Issuance
8

Momentum (81): The shares have been drifting up relative to others.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MAZE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MAZE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26MAZEHigh $110Median $55Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $46Median $55High $110

The green dot is the last close — the median target sits +144.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026BTIGReiteratesBuy$46
14 Apr 2026Truist SecuritiesMaintainsBuy$68 → $64
14 Apr 2026Truist SecuritiesMaintainsBuy—
31 Mar 2026JP MorganMaintainsOverweight—
25 Mar 2026BTIGReiteratesBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Mar 2026Truist SecuritiesInitiatesBuy—
16 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026MizuhoInitiatesOutperform—
9 Mar 2026BTIGReiteratesBuy—
4 Mar 2026GuggenheimMaintainsBuy—
16 Jan 2026BTIGMaintainsBuy—
4 Dec 2025Wells FargoInitiatesOverweight—
3 Dec 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2025WedbushMaintainsOutperform—
29 Sept 2025JP MorganMaintainsOverweight—
18 Sept 2025HC Wainwright & Co.ReiteratesBuy—
15 Sept 2025GuggenheimMaintainsBuy—
12 Sept 2025BTIGMaintainsBuy—
12 Sept 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MAZE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MAZE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Maze Therapeutics, Inc. returned −4.1% against +16.3% for the S&P 500, dividends included.

MAZE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26MAZES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MAZE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
3
Fundamentals

Maze Therapeutics, Inc. (MAZE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
189.5×

Cheaper than 4% of US stocks

Price / sales
61.7×

Cheaper than 5% of US stocks

Price / book
2.7×

Cheaper than 35% of US stocks

EV / EBITDA
−6.6×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−728.1%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−37.3%

Higher than 25% of US stocks

Return on assets
−21.8%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Maze Therapeutics, Inc. (MAZE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Maze Therapeutics, Inc. has a market value of $1.3B and an enterprise value of $951.4M.

  • Revenue in the twelve months to 30 June 2026: $20.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$133.6M, a −668.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.52.

  • Free cash flow in the twelve months to 30 June 2026: −$106.8M.

  • Shares outstanding: 55.5M.

  • Trailing P/E: 189.5×; forward P/E: −7.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Maze Therapeutics, Inc. employs 141 people — $142K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

MAZE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MAZEMaze Therapeutics, Inc.$1.3B
26
REPLReplimune Group, Inc.$1.2B
39
MGTXMeiragtx Holdings plc$1.2B
84
VORVor Biopharma, Inc.$1.3B
15
OMEROmeros Corp.$1.3B
90
AKTSAktis Oncology, Inc.$1.2B
1
APMDApnimed, Inc.$1.2B
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Maze Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MAZE news & analysis

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

The Motley Fool · 11 Sept 2026negative

Maze Therapeutics' Chief Medical Officer Harold Bernstein sold 9,705 shares for approximately $255,000 on September 4, 2026. The sale represented 100% of the insider's directly held common stock before the filing.

Why it matters — A Maze watcher might see the CMO liquidating his entire direct stake as a noteworthy signal regarding insider confidence in the company.

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Maze Therapeutics presented at Citigroup's Biopharma Back to School Summit 2026, where a transcript of the presentation was published. The presentation covers the company's biopharma activities at the event.

Why it matters — A Maze watcher would care because the presentation provides insight into the company's positioning and disclosures shared with investors at a major industry summit.

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Maze Therapeutics announced that company management will participate in three upcoming investor conferences, beginning with a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. The clinical-stage biopharmaceutical company develops small molecule precision medicines for kidney and metabolic diseases.

Why it matters — A MAZE watcher would care because management's participation in multiple investor conferences provides opportunities for the company to present its pipeline and strategy to the investment community.

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Seeking Alpha · 26 Aug 2026neutral

Maze Therapeutics has advanced two lead precision medicine programs: MZE782 for PKU, which showed a best-in-class pharmacodynamic profile in Phase 1 with Phase 2 planned for mid-2026, and MZE829 for APOL1-mediated kidney disease, which achieved strong uACR reductions in early Phase 2 data with pivotal trials planned for the first half of 2027. The company faces competition from Vertex's inaxaplin in the kidney disease space.

Why it matters — MAZE watchers would care because these are updates on the company's two most prominent clinical programs, including timelines for pivotal trials and a noted competitive threat in the kidney disease market.

Maze Therapeutics Announces Appointments to Its Board of Directors

GlobeNewsWire · 13 Aug 2026positive

Maze Therapeutics announced that Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., have joined its Board of Directors, adding clinical and industry experience to the company's leadership.

Why it matters — New board appointments bring additional clinical and pharmaceutical expertise to Maze's leadership as the company advances its pipeline.

FAQ

Frequently asked questions about MAZE stock

What is the MAZE stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Maze Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $46 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MAZE stock a buy right now?

Of the 12 analysts covering Maze Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maze Therapeutics, Inc. 26 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MAZE?

As at 19 Sept 2026, Maze Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).

Will MAZE stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +144.2% from the last close, and Ticker Nerd's factor model ranks Maze Therapeutics, Inc. 26 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MAZE stock forecast for 2030?

No analyst covering Maze Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAZE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $110 over the next 12 months.

How has MAZE stock performed over the past year?

Maze Therapeutics, Inc. returned -4.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Maze Therapeutics, Inc. do?

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity.

What is the latest news on MAZE?

The most recent item we track (The Motley Fool, 11 Sept 2026): "Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000". Maze Therapeutics' Chief Medical Officer Harold Bernstein sold 9,705 shares for approximately $255,000 on September 4, 2026. The sale represented 100% of the insider's directly held common stock before the filing.

Company

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity. The company uses its human genetics-driven Compass platform to identify disease-linked genetic variants and translate those insights into targeted drug candidates. Its current pipeline includes oral programs aimed at genetically defined kidney disorders, reflecting a strategy centered on precision medicine and biologically validated pathways. Maze Therapeutics operates from South San Francisco, California, and is positioned within the broader biotechnology sector as a developer of novel therapies for patients with renal and metabolic conditions.

CEO Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. · 141 employees · United States · https://www.mazetx.com